You have 9 free searches left this month | for more free features.

Topoisomerase Inhibitor

Showing 1 - 25 of 7,493

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Neuroblastoma Trial in Guangzhou (Naxitamab monotherapy, GM-CSF, Irinotecan)

Recruiting
  • Neuroblastoma
  • Naxitamab monotherapy
  • +6 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Aug 31, 2023

Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Tumor, Metastatic Neuroendocrine Carcinoma Trial in United

Recruiting
  • Metastatic Lung Small Cell Carcinoma
  • +16 more
  • Phoenix, Arizona
  • +10 more
Mar 25, 2022

Advanced Cancer Trial in Guangzhou (TQB2102 injection)

Not yet recruiting
  • Advanced Cancer
  • TQB2102 injection
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Feb 23, 2023

Metastatic Colorectal Carcinoma, Metastatic Lung Carcinoma, Metastatic Lung Small Cell Carcinoma Trial in United States

Recruiting
  • Metastatic Colorectal Carcinoma
  • +29 more
  • Los Angeles, California
  • +22 more
Jun 28, 2022

Metastatic Non Small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer Trial in Philadelphia (Etirinotecan pegol

Completed
  • Metastatic Non Small Cell Lung Cancer
  • Recurrent Non Small Cell Lung Cancer
  • Etirinotecan pegol (NKTR-102)
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Apr 1, 2020

Metastatic Colorectal Cancer Trial (AUM001, Pembrolizumab, Irinotecan)

Not yet recruiting
  • Metastatic Colorectal Cancer
  • (no location specified)
Jul 13, 2022

Recurrent Small Cell Lung Carcinoma Trial in Buffalo, Rochester (Laboratory Biomarker Analysis, Pegylated Irinotecan,

Completed
  • Recurrent Small Cell Lung Carcinoma
  • Laboratory Biomarker Analysis
  • +2 more
  • Buffalo, New York
  • +2 more
Mar 3, 2020

Gliomas Trial in New York (Topotecan, Gadolinium, Synchromed II infusion pumps)

Completed
  • Gliomas
  • New York, New York
    Columbia University Irving Medical Center
Jun 30, 2022

HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer Trial in Chicago, Minneapolis (ALX148, Fam-Trastuzumab

Recruiting
  • HER2-positive Breast Cancer
  • +17 more
  • ALX148
  • Fam-Trastuzumab Deruxtecan-Nxki
  • Chicago, Illinois
  • +1 more
May 19, 2023

Tumors, Lymphoma Trial run by the National Cancer Institute (NCI) (LMP400, LMP776)

Completed
  • Neoplasms
  • Lymphoma
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Apr 7, 2022

HRD Cancer, SCLC, Advanced Solid Tumors Trial run by the NCI (Berzosertib, Sacituzumab Govitecan)

Recruiting
  • HRD Cancer
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023

Breast Cancer Trial in United States (Alpelisib, Sacituzumab govitecan)

Recruiting
  • Breast Cancer
  • Fairway, Kansas
  • +6 more
Apr 4, 2022

Acute Myeloid Leukemia Trial in Nanjing (Venetoclax-Decitabine/Azacitidine-Aclarubicin Association,

Recruiting
  • Acute Myeloid Leukemia
  • Venetoclax-Decitabine/Azacitidine-Aclarubicin Association
  • Venetoclax-Decitabine/Azacitidine Association
  • Nanjing, Jiangsu, China
    The First Affiliated Hospital with Nanjing Medical University
Mar 2, 2022

SCLC, Small Cell Cancer, Advanced Solid Tumor Trial run by the NCI (Lurbinectedin, Berzosertib)

Recruiting
  • SCLC
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Beijing (HS-20089)

Not yet recruiting
  • Ovarian Cancer
  • +3 more
  • Beijing, Beijing, China
    Lingying Wu
Aug 22, 2023

Breast Cancer, Colorectal Cancer, Ovarian Cancer Trial in United States (ATRC-101, Pembrolizumab, Pegylated liposomal

Recruiting
  • Breast Cancer
  • +15 more
  • ATRC-101
  • +2 more
  • Phoenix, Arizona
  • +10 more
Sep 28, 2022

Advanced Solid Tumor Trial (HLX43)

Not yet recruiting
  • Advanced Solid Tumor
  • (no location specified)
Oct 30, 2023

Breast Cancer Trial in China (TQB2102 for injection)

Not yet recruiting
  • Breast Cancer
  • TQB2102 for injection
  • Hefei, Anhui, China
  • +20 more
Nov 1, 2023

Urothelial Carcinoma, Urothelial Cancer, Lung Tumors Trial run by the NCI (EP0057, olaparib)

Recruiting
  • Urothelial Carcinoma
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Cancer Trial (Empagliflozin 10 MG)

Not yet recruiting
  • Cancer
  • Empagliflozin 10 MG
  • (no location specified)
Oct 22, 2023

Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers Trial (ABBV-400)

Not yet recruiting
  • Hepatocellular Carcinoma
  • +6 more
  • (no location specified)
Oct 10, 2023

Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Atypical Chronic Myeloid

Active, not recruiting
  • Acute Myeloid Leukemia
  • +9 more
  • Los Angeles, California
  • +5 more
Jan 27, 2023

Gastrointestinal Stromal Tumors Trial in Seoul (Rivoceranib Mesylate, Paclitaxel)

Not yet recruiting
  • Gastrointestinal Stromal Tumors
  • Rivoceranib Mesylate, Paclitaxel
  • Seoul, Korea, Republic of
    Asan Medical Center, University of Ulsan College of Medicine
Jun 7, 2023

Adenocarcinoma, Gastric, Tumor, Breast Trial in Taipei (DS-8201a)

Completed
  • Adenocarcinoma, Gastric
  • Neoplasm, Breast
  • Taipei, Taiwan
  • +1 more
Nov 2, 2022

Small Cell Lung Cancer, Extra-Pulmonary Small Cell Carcinomas Trial run by the NCI (PLX038, Rucaparib)

Active, not recruiting
  • Small Cell Lung Cancer
  • Extra-Pulmonary Small Cell Carcinomas
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023